Skip to content

Ottobock Set for Biggest German IPO Since 2014, Raising €808M

After a failed 2022 attempt, Ottobock is back with a bang. Its IPO could be the largest in Germany this year, buoyed by robust financials and high-profile investor support.

In this image a person's hands are visible. He is holding an injection which is having some text on...
In this image a person's hands are visible. He is holding an injection which is having some text on it.

Biggest IPO of the Year? Ottobock Issues Shares - Ottobock Set for Biggest German IPO Since 2014, Raising €808M

Medical technology giant Ottobock is set to make waves in the German stock market with its Initial Public Offering (IPO) on October 2025. The company's shares will be priced at 66 euros each, aiming to raise approximately 808 million euros and valuing the company at around 4.2 billion euros. This makes it one of the largest IPOs in Germany this year and the biggest since Douglas in 2024.

Ottobock's recent financial performance has been robust. In the first half of 2025, its core business saw underlying EBITDA increase to 175 million euros, while revenue reached 760 million euros. The company, which specializes in medical technology, will start trading its shares on the Frankfurt Stock Exchange from 9:00 AM.

The IPO involves issuing around 12.2 million shares, with most coming from the portfolio of the sole previous owner, Nader Holding. This will result in a free float of approximately 19 percent. Ottobock plans to use about 100 million euros of the raised funds for further acquisitions or investments, with the rest going to Nader Holding.

This IPO comes after a failed attempt in 2022. Despite recent challenges in the IPO environment, Ottobock has secured purchase commitments from billionaire Klaus Michael Kühn and a fund of the US investment company Capital Group.

If successful, Ottobock's IPO could be the largest in Frankfurt since Douglas in 2014. The company's strong financial performance and the support of prominent investors suggest a positive outlook for the IPO and the company's future in the public market.

Read also:

Latest